ArticleInternational journal of general medicine2024
Serum Hsa_circ_0023919 is a Predictive Biomarker of Chemoresistance in CRC Treatment.
Article in International journal of general medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The diversity of available chemotherapeutic modalities for colorectal cancer (CRC) entails the implementation of personalized therapeutic regimens to optimize patient outcomes. Currently, the clinical use of biological markers for treatment selection is inadequate to achieve individualization. Circulatory RNAs (circRNAs), which function as plasma biomarkers, play a critical role in regulating biological processes in different types of cancer. Methods: The samples (serum) were obtained from 80 CRC patients and 80 healthy individuals (controls) to assess the level of hsa_circ_0023919 via qRT-PCR analysis. Results: In findings, hsa_circ_0023919 has a positive association with the disease stage and is greatly elevated in chemoresistant CRC patients. In addition, the area under the curve for hsa_circ_0023919 was modest, and an increase in hsa_circ_0023919 expressions was linked with a decreased overall survival (OS) and progression-free survival (PFS). Serum hsa_circ_0023919 levels serve as a diagnostic indicator for chemoresistance in CRC. Conclusion: The findings suggested that hsa_circ_0023919 contributes to promoting chemoresistance in CRC patients. Consequently, it can be considered a potent therapeutic target for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.